Cardiff Oncology (CRDF) analyst forecast and price target
Analyst forecast
Consensus of 6 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| HC Wainwright & Co. | Upgraded | Neutral → Buy | $9.00 | Sep 15, 2026 |
| William Blair | Downgraded | Outperform → Market Perform | — | Aug 12, 2026 |
| Craig-Hallum | Downgraded | Buy → Hold | $2.00 from $10.00 | Jun 3, 2026 |
| HC Wainwright & Co. | Downgraded | Buy → Neutral | — | Jun 1, 2026 |
| TD Cowen | Downgraded | Buy → Hold | — | Jun 1, 2026 |
| Piper Sandler | Maintained | Overweight | $6.00 from $10.00 | Feb 25, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $10.00 | Jan 28, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $10.00 from $18.00 | Aug 6, 2025 |
| Ladenburg Thalmann | Initiated Coverage | Buy | $19.00 | Jul 8, 2025 |
| Jefferies | Initiated Coverage | Hold | $3.50 | Jun 24, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $18.00 from $17.00 | May 9, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $17.00 from $13.00 | Feb 28, 2025 |
| Piper Sandler | Maintained | Overweight | $10.00 from $7.00 | Dec 13, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $13.00 from $14.00 | Nov 8, 2024 |
| Craig-Hallum | Initiated Coverage | Buy | $8.00 | Sep 6, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $14.00 | May 6, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $14.00 from $12.00 | Mar 6, 2024 |
| Piper Sandler | Maintained | Overweight | $7.00 from $5.00 | Mar 1, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $12.00 from $13.00 | Aug 11, 2023 |
| HC Wainwright & Co. | Maintained | Buy | $13.00 from $14.00 | Aug 8, 2023 |
Frequently asked questions
Is CRDF a buy, sell, or hold?
Analysts covering Cardiff Oncology currently average a Hold rating: 2 buy, 4 hold and 0 sell, from 6 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on CRDF?
On Sep 15, 2026, HC Wainwright & Co. upgraded Cardiff Oncology to Buy with a price target of $9.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.